BRAF and melanoma: For example, BRAF inhibitor-resistant melanoma cells which possess hyperactivation of ERK and AKT to overcome BRAF inhibition, yet they gradually lose autophagic proteins including Atg5 and AMPK while continuously exposed to BRAF inhibitor vemurafenib [34].